MicroRNAs(miRNAs)are involved in lymphoma progression by regulating the tumor microenvironment.Serum miR130b is overexpressed in diffuse large B-cell lymphoma(DLBCL),inducing Th17 cell alterations.To further illustrat...MicroRNAs(miRNAs)are involved in lymphoma progression by regulating the tumor microenvironment.Serum miR130b is overexpressed in diffuse large B-cell lymphoma(DLBCL),inducing Th17 cell alterations.To further illustrate its biological significance and therapeutic rationale,miR130b was detected by quantitative real-time PCR in the serum samples of 532 newly diagnosed DLBCL patients.The mechanism of miR130b on lymphoma progression and the tumor microenvironment was investigated both in vitro and in vivo.Therapeutic targeting miR130b was also evaluated,including OX40 agonistic antibody and lipid nanoparticles(LNPs)-miR130b antagomir.The results showed that serum miR130b significantly correlated with tumor miR130b and serum interleukin-17,indicating lymphoma relapse and inferior survival of DLBCL patients.MiR130b overexpression altered tumor microenvironment signaling pathways and increased Th17 cell activity.As mechanism of action,miR130b downregulated tumor OX40L expression by directly targeting IFNAR1/p-STAT1 axis,recruiting Th17 cells via OX40/OX40L interaction,thereby promoting immunosuppressive function of Th17 cells.In co-culture systems of B-lymphoma cells with immune cells,miR130b inhibited lymphoma cell autophagy,which could be counteracted by OX40 agonistic antibody and LNPs-miR130b antagomir.In murine xenograft model established with subcutaneous injection of A20 cells,both OX40 agonistic antibody and LNPs-miR130b antagomir remarkably inhibited Th17 cells and retarded miR130b-overexpressing tumor growth.In conclusion,as an oncogenic biomarker of DLBCL,miR130b was related to lymphoma progression through modulating OX40/OX40L-mediated lymphoma cell interaction with Th17 cells,attributing to B-cell lymphoma sensitivity towards OX40 agonistic antibody.Targeting miR130b using LNPs-miR130b antagomir could also be a potential immunotherapeutic strategy in treating OX40-altered lymphoid malignancies.展开更多
基金the National Natural Science Foundation of China(81830007,82130004,81900193,and 21871180)Chang Jiang Scholars Program,Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support(20152206 and 20152208)+5 种基金Shanghai Sailing Program(19YF1430900)Clinical Research Plan of Shanghai Hospital Development Center(SHDC2020CR1032B)Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine(DLY201601)Multicenter Hematology-Oncology Programs Evaluation System(M-HOPES)Collaborative Innovation Center of Systems Biomedicinethe Samuel Waxman Cancer Research Foundation.
文摘MicroRNAs(miRNAs)are involved in lymphoma progression by regulating the tumor microenvironment.Serum miR130b is overexpressed in diffuse large B-cell lymphoma(DLBCL),inducing Th17 cell alterations.To further illustrate its biological significance and therapeutic rationale,miR130b was detected by quantitative real-time PCR in the serum samples of 532 newly diagnosed DLBCL patients.The mechanism of miR130b on lymphoma progression and the tumor microenvironment was investigated both in vitro and in vivo.Therapeutic targeting miR130b was also evaluated,including OX40 agonistic antibody and lipid nanoparticles(LNPs)-miR130b antagomir.The results showed that serum miR130b significantly correlated with tumor miR130b and serum interleukin-17,indicating lymphoma relapse and inferior survival of DLBCL patients.MiR130b overexpression altered tumor microenvironment signaling pathways and increased Th17 cell activity.As mechanism of action,miR130b downregulated tumor OX40L expression by directly targeting IFNAR1/p-STAT1 axis,recruiting Th17 cells via OX40/OX40L interaction,thereby promoting immunosuppressive function of Th17 cells.In co-culture systems of B-lymphoma cells with immune cells,miR130b inhibited lymphoma cell autophagy,which could be counteracted by OX40 agonistic antibody and LNPs-miR130b antagomir.In murine xenograft model established with subcutaneous injection of A20 cells,both OX40 agonistic antibody and LNPs-miR130b antagomir remarkably inhibited Th17 cells and retarded miR130b-overexpressing tumor growth.In conclusion,as an oncogenic biomarker of DLBCL,miR130b was related to lymphoma progression through modulating OX40/OX40L-mediated lymphoma cell interaction with Th17 cells,attributing to B-cell lymphoma sensitivity towards OX40 agonistic antibody.Targeting miR130b using LNPs-miR130b antagomir could also be a potential immunotherapeutic strategy in treating OX40-altered lymphoid malignancies.
